Patheon has signed an agreement to acquire a new active pharmaceutical ingredients (API) manufacturing facility in Florence, South Carolina, US, from Roche.
Go deeper with GlobalData
Under the agreement, the site will be purchased by Patheon for an immaterial sum, as well as the cost of associated inventory and spare parts.
Patheon has also signed a supply arrangement with Roche, which will help defray the costs associated with running the site for the next few years.
Patheon CEO James Mullen said: “As the only end-to-end provider of pharma development and manufacturing services, Patheon is uniquely positioned to integrate this new site into our global network and quickly leverage the capabilities with existing and new clients.
“The company will benefit from the additional North American API capacity and adds a state-of-the-art facility with approximately 200 scientific and manufacturing professionals.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe Florence facility is expected have a similar financial profile to the company’s other sites in its drug substance segment.
The 1,100 acre, 300,000ft² facility will have manufacturing capacity for API, ranging from development to manufacturing services.
With the addition of this site, Patheon will be able to expand its capacity for manufacturing highly potent compounds.
Furthermore, the acquisition will add capabilities to support solid-state chemistry, micronisation, and eventually, commercial spray drying.
The site features reactors ranging from 50l to 11,000l producing multiple products simultaneously, and will provide Patheon with a US API operation that can support products from clinical scale to commercial manufacturing.
Image: Florence, South Carolina, manufacturing site acquired by Patheon. Photo: courtesy of Business Wire.
